Background--Recent recommendations suggest that in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and coexistent significant coronary artery disease, the latter should be treated before the index procedure; however, the evidence basis for such an approach remains limited. We performed a systematic review and meta-analysis to study the clinical outcomes of patients with coronary artery disease who did or did not undergo revascularization prior to transcatheter aortic valve implantation.
associated with worse postoperative outcomes, although with no negative impact on operative and 1-year mortality. 5, 6 Nevertheless, the role of revascularization in long-term morbidity and mortality in octogenarians is still not clear. 7 The prevalence of CAD in the population undergoing transcatheter aortic valve implantation (TAVI) is higher than that in those undergoing surgical aortic valve replacement, and depending on the definition, the presence of significant CAD ranges from 50% to 75%. [8] [9] [10] [11] [12] Notably, randomized clinical trials that led to the approval of TAVI devices in United States required revascularization of significant CAD affecting main epicardial vessels within 30 days of TAVI. In this context, it has been recommended to perform percutaneous coronary intervention (PCI) or a hybrid procedure to revascularize patients with significant CAD. [13] [14] [15] Favorable outcomes associated with prior-TAVI PCI have been reported in single-center studies with relatively small sample sizes, although these were often underpowered for the end points studied and were subject to significant selection biases. In addition, data on whether revascularization should be performed before or in the same setting are still scant. The aim of this report was to perform a systematic review and meta-analysis to assess the evidence basis and clinical outcomes associated with TAVI procedures performed with and without revascularization of coexistent CAD with PCI.
Methods Search Strategy
We conducted a search of Medline, Embase, Google Scholar, Science Direct, Web of Science, and conference abstracts from conception to September 2016 using OvidSP. One study published after the systematic search was updated from its previous publication in a conference abstract format and then included in the qualitative synthesis. The following terms were used: (transcatheter aortic valve implantation OR transfemoral aortic valve implantation OR transapical aortic valve implantation OR trans-subclavian aortic valve implantation OR TAVI OR transcatheter aortic valve replacement OR TAVR) AND (percutaneous coronary intervention OR PCI OR coronary angioplasty). Institutional review board approval and patient consent were not required because of the nature of this study as a systematic review and meta-analysis.
Study Selection
The abstract and titles yielded by the search were screened by 2 independent investigators (R.A.K. and C.S.K.) against the inclusion criteria. Additional studies were retrieved by checking the bibliography of included studies and relevant reviews. The full reports of potentially relevant studies were retrieved, and data were independently extracted on study design, participant characteristics, treatment groups, outcome events, follow-up, and results. Any discrepancies between reviewers were resolved by discussion after consulting a third investigator (R.B.).
Eligibility Criteria
We included only studies published in English that evaluated patients with underlying CAD who underwent PCI as a revascularization strategy prior to or concomitantly with TAVI versus no revascularization. In terms of outcomes, studies included must have evaluated ≥1 of the following
Clinical Perspective
What Is New?
• The prevalence of coexisting coronary artery disease in populations undergoing transcatheter aortic valve implantation averaged 70%.
• Anatomically significant coronary artery disease was inconsistently defined and varied from at least ≥50% to >90% diameter stenosis.
• None of the available data reported on the use of functional assessment for coronary artery disease significance.
• Major vascular complications and 30-day mortality may be increased among patients undergoing percutaneous coronary intervention revascularization before transcatheter aortic valve implantation procedures.
• No significant benefit was observed with percutaneous coronary intervention revascularization in terms of 1-year mortality.
• The timing, a priori versus concomitant percutaneous coronary intervention revascularization strategies, showed comparable results.
What Are the Clinical Implications?
• Routine revascularization before or during transcatheter aortic valve implantation confers no clinical advantage with respect to several patient-important clinical outcomes.
• In the absence of definitive evidence, careful evaluation of patients by a dedicated heart team is of paramount importance to identify patients for whom the benefits of elective revascularization are balanced against the potential risks.
• Randomized controlled trials are needed to determine the role of routine revascularization in patients with significant coronary artery disease undergoing transcatheter aortic valve implantation.
events: 30-day and 1-year mortality, myocardial infarction (MI), vascular complications, bleeding, neurological events (stroke or transient ischemic attack), or acute kidney injury (AKI). End points were reported, when available, in accordance to Valve Academic Research Consortium 2 definitions. 16 The reporting of outcomes had to include either crude events in each group or any risk or odds estimate (risk ratio or odds ratio [OR]) with 95% confidence intervals (CIs). There was no restriction based on the design of the study or the duration of follow-up. We excluded isolated case reports or case series (≤3 patients), reviews, and editorial comments on the subject. When duplicate reports of the same study were identified, only the report with the most complete data set and detailed methodology description was included. A flow diagram is provided following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses 17 ; Figure 1 ).
Quality and Risk of Bias Assessment
To assess the quality of included cohort studies, we used the Newcastle-Ottawa Scale. 18 The outcomes of interest and follow-up were also extracted on a preformatted table. Disagreements were resolved by consensus after consultation with an investigator (R.B.). Risk of bias was assessed by considering the ascertainment of treatment groups, the ascertainment of outcomes, loss to follow-up, and potential confounders in the data analysis.
Data Analysis
We used RevMan (Review Manager version 5.1.7, Nordic Cochrane Centre, Denmark) to perform random-effects metaanalysis using the Mantel-Haenszel method to determine pooled ORs for dichotomous data with regard to post-TAVI outcomes with and without PCI revascularization. To ensure a meta-analysis with clinically transferable results, we included only studies in which the methodology or data set permitted adjudication of CAD prevalence in the TAVI-alone group. The Cochrane Q statistic (I 2 ) was used to assess the consistency among studies, with I 2 <25% considered low, I 2 values of 25% to 50% considered moderate, and I 2 >75% considered high statistical heterogeneity. 19 If there were insufficient data or studies for meta-analysis, we pooled the studies using weighted average or performed narrative synthesis of studies that were too heterogeneous to pool. Sensitivity analyses were performed to assess the potential influence of any estimates on treatment effect or association that were derived from the mean by excluding a study considered as an outlier. 20 In addition, sensitivity analyses further assessed for potential differences between random-and fixed-effects models, excluding studies in which one of the treatment arms had no events. Subgroup analyses were performed to determine whether treatment effect was influenced by studies reporting a population with 100% versus >50% (but <100%) of the patients presenting with CAD. Meta-regression was performed to further investigate the potential source of clinical heterogeneity 21 and to determine the influence of CAD on outcomes. The metareg function (STATA 14.0) was used to undertake metaregression with log-risk estimates and the standard error determined from 95% CIs for the log-risk estimates. Prevalence of CAD was calculated by averaging the percentage of patients with CAD in TAVI-PCI and TAVI-alone groups. Two-sided P values of <0.05 were considered statistically significant.
Results

Study Population
A total of 24 observational studies [9] [10] [11] [12] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] including 7128 participants met the inclusion criteria for the systematic review; among these, 9 studies* met criteria for the metaanalysis, evaluating 3858 participants (Figure 1 ) of which 983 Items for Systematic Reviews and Meta-Analyses).
* References 9, 10, 12, 25, 31, 32, 35, 37, 40. underwent TAVI with PCI revascularization strategy. The mean age was 85.3 years and 48.4% were female in 14 studies that reported both age and gender. † Anatomically significant CAD was inconsistently defined and included at least ≥50% diameter stenosis in 7 studies, 9, 10, 12, 28, 29, 34, 38 >70% stenosis in 5 studies, 11, 24, 31, 36, 37 and >90% stenosis in 1 study. 35 A total of 4 studies 11, 35, 37, 38 defined >50% stenosis when located in the left main. None of the studies reported on the use of functional assessment for CAD significance. Further details on study design and participants baseline characteristics are presented in Tables 1 and 2 .
Quality Assessment
Ascertainment of outcomes varied from medical record reviews to prospective evaluation with adjudicated clinical end points. All studies contained no major loss to followup, and the overall quality level was average. Follow-up of patients varied from in-hospital outcomes, clinical visits, and telephone calls up to 4 years from the date of implant. Although follow-up among studies was inconsistent, the most common time points were at 30 days and 1 year. The Newcastle-Ottawa quality assessment is presented in Table 3 .
In-Hospital, 30-Day, and Long-Term Outcome With PCI Versus TAVI Alone
Device type, access site, procedure-related outcomes, and follow-up assessment for all included studies reporting crude rate of events are summarized in Table 4 . Crude outcomes for strategies with versus without revascularization (PCI) are shown in Figure 4 ). Table 2 . Table 4 . Table 4 . Table 4 . Table 4 . 
Coexisting Coronary Artery Disease
The prevalence of coexisting CAD was reported in both revascularized and nonrevascularized groups in 9 studies, ¶ and varied from 51.4% to 100%. Consequently, we conducted a subgroup analysis of clinical outcomes comparing studies reporting populations with 100% versus >50% (but <100%) of the patients presenting with CAD.
In subgroup analysis including studies in which the prevalence of CAD was 100%, the OR for 30-day mortality among patients who underwent PCI was 0.80 (95% CI, 0.28-2.27), whereas in studies in which the prevalence of CAD was >50% (but <100%), more patients who received PCI died (OR: 1.49; 95% CI, 1.12-1.98; P=0.006; heterogeneity: P=0.45, I 2 =0%). The overall difference showed significant effect estimates (OR: 1.42; 95% CI, 1.08-1.87; P=0.01; heterogeneity: P=0.63, I
2 =0%) without significant interaction (P=0.65, I 2 =20%). No significant differences in effect estimates were observed in terms of cardiovascular (OR: 1.03; 95% CI, 0.35-2.99) and 1-year (OR: 1.05; 95% CI, 0.71-1.56) mortality rates. Similar effect estimates were found for the 2 strategies in the remaining analyzed variables ( Figure 5 ). Sensitivity analysis comparing random-versus fixed-effects models and excluding studies with no events in one of the treatment arms is shown in Table 6 . The results suggest no differences in effect estimates between the 2 models or after excluding studies with no events in one of the treatment arms. Metaregression analysis was conducted to further investigate potential sources of clinical heterogeneity based on the prevalence of CAD. The results rule out a strong magnitude of the effect to influence any of the analyzed outcomes (Table 7) .
Discussion
The results of this meta-analysis of 9 observational studies including 3858 patients show that PCI revascularization before (prior to and concomitant) TAVI may be associated with an increased risk of major vascular complications and 30-day mortality, although by 1 year, this association was no longer present. In addition, comparing TAVI with and without revascularization, there were no significant differences in rates of MI, bleeding, AKI/hemodialysis, or cerebrovascular accidents at 30 days. Notably, we found that the evidence basis consists of poor-quality studies confounded by selection bias, thus emphasizing the need for randomized controlled trials. Table 4 . Values are expressed as the occurrence of an event/sample size. PCI indicates percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.
Assessing the Severity of CAD in Patients Undergoing TAVI
The optimal treatment of CAD in patients with TAVI remains to be elucidated. Although Dewey et al 8 showed that CAD is an independent predictor of early and midterm survival, this finding was not supported by other studies. 37, 38, 42, 43 In addition, Khawaja and colleagues 37 showed that CAD was not a predictor of worse outcome, albeit in patients exhibiting a SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score >9. Chauhan and colleagues 43 found no significant association between the SYNTAX or Duke Myocardial Jeopardy score with rates of their prespecified primary composite end point (all-cause mortality, major adverse cardiovascular and cerebrovascular event, and postoperative coronary revascularization) or secondary outcomes of the 30-day and 1-year composite end point. Moreover, the authors went further and questioned the role of coronary angiography as part of the TAVI workup. 43 More recently, Paradis and colleagues 41 showed that neither the severity of CAD nor the residual SYNTAX score after revascularization was associated with worse outcomes at 30 days and 1 year after TAVI.
As mentioned previously, the reported prevalence of CAD in the population undergoing TAVI varies depending on the definitions used to define significance (Table 1) and can be as high as 75%. [8] [9] [10] [11] [12] The severity of CAD in AS patients has historically been assessed using angiography to further determine the need for revascularization; however, it is well known that functionally guided fractional flow reserve PCI strategies have shown improvements in patient outcome. 44 Nonetheless, functional assessment of CAD in the presence of AS becomes difficult due to diffuse subendocardial ischemia leading to myocardial fibrosis as well as left ventricular remodeling and, often, severe hypertrophy. 45, 46 Consequently, coronary physiology is altered in patients with severe AS, and although the use of fractional flow reserve has not been validated for this group, fractional flow reserve has been performed safely in contemporaneous studies of patients with severe AS.
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Coronary Revascularization and TAVI Outcomes
Our meta-analysis suggests that routine revascularization of patients with severe AS and concomitant CAD undergoing TAVI may be associated with an increased risk of major vascular complications and 30-day mortality, although the latter association was no longer present by 1 year. In this regard, Van Mieghem et al 29 have shown no significant difference between complete versus incomplete revascularization or for SYNTAX scores ≥8 versus <8. One of the theoretical arguments to support revascularization prior to TAVI is the anxiety that periprocedural MI might occur during the hypotension induced by rapid pacing for valvuloplasty or during valve delivery. Notably, Griese et al 33 showed that revascularization was associated with increased 30-day MI compared with TAVI alone; however, the study did not ascertain the prevalence of CAD in the TAVI-alone group or, indeed, the indication for PCI. As such, this study was excluded from our meta-analysis. Singh and colleagues 40 showed worse 30-day outcomes when PCI was performed during the same admission, although, as above mentioned, this observation might have been driven by the difference in the reported prevalence of CAD between groups or by a questionable definition of CAD using International Classification of Diseases, Ninth Revision coding. Higher 30-day mortality could also be associated with a higher preoperative risk profile, meaning that the PCI group may have been a higher risk cohort, translating into worse outcome; however, the authors did not report adjusting for preprocedural risk scoring. Importantly, our analysis shows that when both groups had 100% prevalence of CAD, there was no significant difference in treatment effect estimates, likely due to a small event rates (Figure 2A) . Moreover, metaregression analysis suggests that differences in the prevalence of CAD did not influence this outcome. Finally, the presence of multiple comorbid conditions explains overall 30-day mortality, since cardiovascular mortality was similar.
Timing for Revascularization: Concomitant Versus A Priori Approach
Performing TAVI shortly after PCI mandates that the TAVI procedure be performed while a patient is treated with dual antiplatelet therapy, potentially increasing bleeding risk; however, our analysis shows that major and minor bleeding complications were not significantly different between pre-TAVI PCI and isolated TAVI approaches. Studies that compared concomitant and a priori revascularization approaches found no significant differences for AKI and the need for hemodialysis. 10, 23, 33 Interestingly, one would expect that the likelihood of AKI increases with a concomitant approach, owing to the larger contrast volumes and higher number of catheter manipulations; however, as reported previously, contrast amount per se was not associated with AKI during TAVI procedures. 52 In addition, in most studies that reported the incidence of AKI, PCI was performed a priori rather than in the same setting (1 study only; Figures 3 and 4) . This finding likely reflects the influence of confounding variables because studies were not statistically powered to infer for AKI due to the low event rate. The revised American guidelines on valvular heart disease have downgraded to class IIa (evidence C) the role of coronary revascularization at the time of surgical aortic valve replacement. 3 Recommendations focused on TAVI 
Limitations
The present study has several limitations. The main limitations are the small numbers of studies, patients, and events informing each outcome and the nonrandomized nature of the included studies, which introduced selection bias. Importantly, the decision to perform PCI as revascularization versus medical management for CAD was at the discretion of the heart team and without consistent selection criteria. In this regard, the decision to undertake PCI may relate to unstable symptoms, limiting angina, or patients considered to be at higher risk. Individual-patient level data were not available, precluding more robust adjustment for any differences in clinical or anatomical variables or comparisons of severity or risk across the cohorts. Finally, one should bear in mind that once TAVI is extended to lower risk younger and less morbid patients, who also exhibit longer life expectancy, it may be beneficial to perform pre-TAVI revascularization to prevent potential problematic coronary artery accessibility in the future. The results of the ACTIVATION trial 53 will provide further insight into optimal revascularization strategies in patients with CAD undergoing TAVI.
Conclusion
Our findings suggest that revascularization before or during TAVI confers no clinical advantage with respect to several patient-important clinical outcomes and may be associated with an increased risk of major vascular complications and 30-day mortality. These data, however, are based on observational studies including initial high-risk cohorts of patients with limited follow-up and may not be applicable to lower risk cohorts with greater life expectancy. Randomized controlled trials are needed to determine the role of routine revascularization in patients with significant CAD undergoing TAVI. Meanwhile, in the absence of definitive evidence, careful evaluation of patients on an individual basis by a dedicated heart team is of paramount importance to identify patients, such as those with significant CAD affecting proximal main epicardial vessels, for whom the benefits of elective revascularization are balanced against the potential risks.
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